Research Topics
| James S KahnSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modelingRomulus Breban
Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA
BMC Public Health 9:S11. 2009..Current measures of the clinical efficacy of antiretroviral therapy (ART) in the treatment of HIV include the change in HIV RNA in the plasma and the gain in CD4 cells...
Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trialJ Kahn
Positive Health Program University of California San Francisco, San Francisco General Hospital, 94110, USA
JAMA 282:2305-12. 1999..Adefovir dipivoxil is a nucleotide analog that has demonstrated effective antiretroviral activity against human immunodeficiency virus (HIV) with once-daily administration...
Mentoring the next generation of HIV prevention researchers: a model mentoring program at the University of California San Francisco and Gladstone Institute of Immunology and Virology Center for AIDS researchJames Kahn
Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA
J Acquir Immune Defic Syndr 47:S5-9. 2008..We piloted a multidiscipline mentoring program targeting postdoctoral scholars and early career faculty concentrating on HIV/AIDS research...- Mentoring early-career scientists for HIV research careersJames S Kahn
Department of Medicine, University of California, San Francisco, CA 94110, USA
Am J Public Health 99:S37-42. 2009..Effective mentoring by focused mentors will likely contribute to the skills and networks of investigators necessary for the next generation of HIV investigators... - What it takes: characteristics of the ideal personal health recordJames S Kahn
San Francisco General Hospital, USA
Health Aff (Millwood) 28:369-76. 2009..However, in the future, when these concerns are addressed, and health data are portable and understandable (in both content and format), PHRs will likely prove to be invaluable... - Personal health records in a public hospital: experience at the HIV/AIDS clinic at San Francisco General HospitalJames S Kahn
San Francisco General AIDS Program, Department of Medicine, University of California San Francisco, San Francisco, California 94110, USA
J Am Med Inform Assoc 17:224-8. 2010..Patients in a safety net setting will access and use an online PHR... - Preventing hepatitis A and hepatitis B virus infections among men who have sex with menJames Kahn
Department of Medicine, Positive Health Program, University of California, San Francisco, and San Francisco General Hospital, San Francisco, CA 94110, USA
Clin Infect Dis 35:1382-7. 2002..It is important for health care providers to educate and vaccinate their at-risk male patients against hepatitis A and hepatitis B virus infections... - Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP StudyJ O Kahn
Positive Health Program, Dept of Medicine, University of California San Francisco, at San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
J Infect Dis 183:707-14. 2001..PEP, after nonoccupational HIV exposure, is feasible for persons at risk for HIV infection... - Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trialJ O Kahn
San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
JAMA 284:2193-202. 2000..Agents that enhance the immunologic mechanism for viral recognition might reduce disease progression... - The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementationElvin H Geng
Division of HIV AIDS, San Francisco General Hospital, and Department of Medicine, 995 Potrero Avenue, San Francisco, CA 94110, USA
Clin Infect Dis 53:1008-14. 2011..Subsequently, the San Francisco General Hospital (SFGH) HIV/AIDS Service performed the SFGH 5164 Initiative to disseminate and implement the findings of ACTG 5164... - 'Mobile' health needs and opportunities in developing countriesJames G Kahn
University of California, San Francisco, CA, USA
Health Aff (Millwood) 29:252-8. 2010..We examine various m-health applications and define the risks and benefits of each. We find positive examples but little solid evaluation of clinical or economic performance, which highlights the need for such evaluation... - Training the next generation of research mentors: the University of California, San Francisco, Clinical & Translational Science Institute Mentor Development ProgramMitchell D Feldman
Department of Medicine, University of California, San Francisco, USA
Clin Transl Sci 2:216-21. 2009..MITs reported increased confidence in overall and specific mentoring skills after completion of the MDP. The MDP can serve as a model for other institutions to develop the next generation of clinical-translational research mentors... - Characterizing HIV transmission networks across the United StatesJeannette L Aldous
Division of Infectious Diseases, University of California, San Diego, 200 W Arbor Dr, MC 8208, San Diego, CA 92103, USA
Clin Infect Dis 55:1135-43. 2012..Clinically, human immunodeficiency virus type 1 (HIV-1) pol sequences are used to evaluate for drug resistance. These data can also be used to evaluate transmission networks and help describe factors associated with transmission risk... - A cross-sectional study of barriers to personal health record use among patients attending a safety-net clinicJoan F Hilton
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America
PLoS ONE 7:e31888. 2012.... - A mentor development program for clinical translational science faculty leads to sustained, improved confidence in mentoring skillsMitchell D Feldman
Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
Clin Transl Sci 5:362-7. 2012..We also describe a number of new initiatives to support mentoring at UCSF that have evolved from the MDP. To our knowledge, this is the first evaluation of the long-term impact of a mentor training program for CT researchers... - A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIVMichelle E Roland
Positive Health Program, Department of Internal Medicine, San Francisco General Hospital, San Francisco, California, USA
Clin Infect Dis 53:76-83. 2011..Intensive risk reduction and adherence counseling appear to be effective but are resource intensive. Identifying simpler interventions that maximize the HIV prevention potential of PEP is critical... - Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divideDavid P Wilson
Semel Institute for Neuroscience and Human Behavior, and Department of Biomathematics, David Geffen School of Medicine, University of California, 1100 Glendon Avenue, Penthouse 2, Los Angeles, CA 90024, USA
Proc Natl Acad Sci U S A 103:14228-33. 2006..Decisions about allocating scarce drugs should consider treatment equity as well as epidemiological consequences. Notably, a Durban-only DAS would lead to new disparities in healthcare between urban and rural areas in KwaZulu-Natal... - Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapyMark A Jacobson
Positive Health Program, Department of Medicine, University of California, San Francisco, USA
AIDS 17:917-9. 2003 - HIV RNA testing in the context of nonoccupational postexposure prophylaxisMichelle E Roland
Positive Health Program at San Francisco General Hospital, Department of Medicine, University of California, San Francisco, CA 94110, USA
J Infect Dis 190:598-604. 2004..The specificity and positive predictive value of human immunodeficiency virus (HIV) RNA assays have not been evaluated in the setting of postexposure prophylaxis (PEP)... - Use of laboratory tests and clinical symptoms for identification of primary HIV infectionFrederick M Hecht
Positive Health Program HIV Section at San Francisco General Hospital, tUniversity of California at San Francisco, 94110, USA
AIDS 16:1119-29. 2002..False-positive results can be reduced through duplicate testing and considering tests < 5000 copies/ml as indeterminate results requiring additional testing. p24 antigen was more specific than HIV-1 RNA testing but less sensitive... - Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletionRonnie L Gascon
University of California at San Francisco, Department of Medicine, 94110, USA
J Acquir Immune Defic Syndr 30:146-53. 2002..002). We conclude that monocyte activation as defined by elevation of CD14/DR expression correlates to CD4 T-cell depletion in primary HIV infection, and is predictive of a poor CD4 T-cell response to HAART in a subset of patients... - Development of WF10, a novel macrophage-regulating agentMichael S McGrath
AIDS Immunobiology Research Laboratory, San Francisco General Hospital Medical Center, CA 94110, USA
Curr Opin Investig Drugs 3:365-73. 2002..WF10 is currently being studied in the US, Europe and Asia for treatment of late-stage HIV disease, as well as recurrent prostate cancer, late post-radiation cystitis, autoimmune disease and chronic active hepatitis C disease... - Time trends in primary HIV-1 drug resistance among recently infected personsRobert M Grant
Gladstone Institute of Virology and Immunology, PO Box 914100, San Francisco, CA 94141, USA
JAMA 288:181-8. 2002..Transmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1) may increase with wider use of antiretroviral therapy... - Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversionDon E Smith
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
AIDS Res Hum Retroviruses 19:189-99. 2003..Despite poorer prognostic markers at baseline ES subjects achieved responses similar to those of LS subjects after 1 year of treatment... - Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAARTBeatriz Martinez-Mariño
Department of Medicine, University of California, San Francisco, San Francisco, CA 94143 1270, USA
AIDS 18:1991-9. 2004..To determine the effect of interleukin-2 (IL-2) therapy on immunologic and virologic responses in subjects with acute or recent HIV infection already receiving highly active antiretroviral therapy (HAART)... - Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virusSteven D Pinkerton
Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI 53202, USA
Arch Intern Med 164:46-54. 2004..CONCLUSIONS: For this study population, HIV PEP was cost-effective by conventional standards and cost-saving for persons seeking PEP after male-male receptive anal intercourse... - Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behaviorJeffrey N Martin
Department of Epidemiology and Biostatistics, the Center for AIDS Prevention Studies, and San Francisco, California 94105, USA
AIDS 18:787-92. 2004..Coupled with prior safety and feasibility data, this lack of behavioral disinhibition suggests that use of PEP should be routinely considered following high-risk sexual exposures... - Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral loadSteven G Deeks
San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
Blood 104:942-7. 2004..These data indicate that immunologic activation set point is established early in HIV infection, and that this set point determines the rate at which CD4+ T cells are lost over time... - Seroconversion following nonoccupational postexposure prophylaxis against HIVMichelle E Roland
Positive Health Program at San Francisco General Hospital, California, USA
Clin Infect Dis 41:1507-13. 2005..We sought to describe the occurrence and circumstances of HIV seroconversion following nonoccupational PEP... - Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United StatesSteven D Pinkerton
Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53202, USA
AIDS 18:2065-73. 2004..To evaluate the cost-effectiveness of HIV postexposure prophylaxis (PEP) following sexual or injection-related exposures in 96 metropolitan statistical areas in the United States (MSA)... - Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infectionJason D Barbour
Gladstone Institute of Virology and Immunology, University of California, San Francisco, USA
J Infect Dis 190:251-6. 2004..The pol RC value of 43% may represent a threshold below which HIV-1 has lowered virulence and is less able to deplete CD4(+) T cell counts... - Cohort profile: the Centers for AIDS Research Network of Integrated Clinical SystemsMari M Kitahata
Department of Medicine, University of Washington, Seattle, 98195, USA
Int J Epidemiol 37:948-55. 2008 - Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infectionMarcus Altfeld
Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Boston, Massachusetts, USA
AIDS 17:2581-91. 2003..CONCLUSION: These data demonstrate that host genetic factors can influence the clinical manifestations of acute HIV-1 infection and provide a functional link between HLA-B57 and viral immune control...
Research Grants
- Observational Cohort of HIV-Infected PersonsJames Kahn; Fiscal Year: 2005..Dr. Kahn's research program has the enthusiastic support of his deuartment. the leadership of the AIDS Research Institute at UCSF and other nationally recognized clinical researchers. ..
- Integrating HIV Resistance Data into the CNICS CohortJames Kahn; Fiscal Year: 2004..In this application we focus on adding the new data elements of viral resistance to the CNICS research network..
- Mentoring HIV and Translational Scientists and Developing an EMR Based ResearchJames Kahn; Fiscal Year: 2007....